2409088-11-3
2409088-11-3
Chemical Structure
Brogidirsen
Synonym(s): NS 089; NCNP 02
- CAS No.: 2409088-11-3
- Formula:C280H440N119O105P23
- Molecular Weight:7865.60
IUPAC Name: N-(9-((2R,3R,4R,5R)-3-((tert-butyldimethylsilyl)oxy)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide
SMILES: [Brogidirsen]
Biological Activity: Brogidirsen (NS 089; NCNP 02) is a a dual-targeting antisense oligonucleotide. Brogidirsen can induce dystrophin protein experession. Brogidirsen can be used for the research of Duchenne muscular dystrophy[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Brogidirsen | Brogidirsen (NS 089; NCNP 02) is a a dual-targeting antisense oligonucleotide. Brogidirsen can induce dystrophin protein experession. Brogidirsen can be used for the research of Duchenne muscular dystrophy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Aoki Y, et al. Brogidirsen-The First Dual-Targeting Exon 44 Skipping Drug for Duchenne Muscular Dystrophy: Safety, Tolerability, and High Dystrophin Restoration in Long-Term Clinical Studies[C]//MOLECULAR THERAPY. 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA: CELL PRESS, 2025, 33(4).
- [2]. Komaki H, et al. Phase 1/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy. Cell Rep Med. 2025;6(1):101901. [Content Brief]
Keywords
